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One Sentence Summary:  
Interleukin-2 controls the protein composition of T cells to regulate their responses to 
environmental stimuli.  
 
Abstract: 
Interleukin-2 (IL-2) and Janus kinases (JAKs) regulate transcriptional programs and 
protein synthesis to control the protein content and biomass of effector CD8+ 
cytotoxic T cell (CTL) differentiation. Using high-resolution mass spectrometry, we 
have generated an in-depth characterisation of how IL-2 and JAKs configure the CTL 
proteome. We found that IL-2-JAK1/3 signaling selectively regulated protein 
expression, influencing the levels of critical cytokines and effector molecules in T 
cells. Moreover, IL-2 controlled the expression of proteins that support core metabolic 
processes essential for cellular fitness. One fundamental insight was the dominant role 
for IL-2 in controlling how effector T cells respond to their microenvironment. IL-2-
JAK1/3 signaling pathways thus controlled abundance of nutrient transporters, 
nutrient sensors and critical oxygen sensing molecules. These data provide key 
insights of how IL-2 controls T cell function and highlight signaling mechanisms and 
transcription factors that link oxygen sensing to transcriptional control of CD8+ T cell 
differentiation. 
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Main Text: 
Introduction 
Interleukin-2 (IL-2), a member of the γc chain cytokine family, has numerous roles in 
orchestrating immune responses, including controlling the proliferation and 
differentiation of CD4+ and CD8+ effector T cells (1-5). This vital role in controlling 
T cell function and fate has made manipulation of IL-2 signaling an attractive aim for 
immunotherapies. Hence, IL-2 was one of the first cytokines used in immunotherapy 
to increase T cell responses. IL-2 is also used to expand tumor-specific T cells and 
chimeric antigen receptor redirected T cells (CAR-T cells) ex vivo before adoptive 
transfer to patients (6, 7). IL-2 signals via the tyrosine kinases JAK1 and JAK3, and, 
hence, JAK1/3-specific inhibitors such as Tofacitinib have been developed to 
modulate IL-2 immunoregulatory pathways to treat autoimmune and inflammatory 
conditions. Moreover, the pleiotropic role of IL-2 in controlling both pro-
inflammatory effector T cell responses and the anti-inflammatory homeostasis of 
regulatory T cells has stimulated the development of strategies using modified IL-2 
proteins with altered receptor binding (8) and anti-cytokine antibodies (4, 9) to 
manipulate IL-2 signaling responses for therapies.  
 
In terms of CD8+ cytotoxic T lymphocytes (CTL), IL-2 was first studied because of 
its ability to drive T cell growth and T cell clonal expansion (6, 10, 11). IL-2, thus, 
regulates expression of transcriptional programs that are required for cell cycle 
progression and proliferation. IL-2 also controls the production of interferon gamma 
(IFNg) and perforin/granzyme effector molecules and regulates the expression of 
adhesion molecules and chemokine receptors that dictate the balance of cell 
trafficking to secondary lymphoid organs or peripheral tissues. IL-2 can, thus, direct 
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effector CTL differentiation at the expense of memory CD8+ T cell development (12-
15). The best characterized IL-2-induced gene transcriptional programs are mediated 
by signal transducer and activator of transcription 5 (STAT5) proteins (3, 16-18) and 
by MYC (19).  
 
However, IL-2-JAK1/3 control of serine/threonine kinase signaling networks is also 
very important. For example, IL-2 controls the activity of mammalian target of 
rapamycin complex 1 (mTORC1)-mediated signaling pathways that regulate the 
expression of inflammatory cytokines, cytolytic effector molecules, glucose 
transporters and glucose and fatty acid metabolism in CTL (20-23). The IL-2-JAK-
regulated phosphoproteome of CTL is dominated by proteins that regulate mRNA 
stability and protein translational machinery (24). Moreover, a key role for IL-2 is to 
sustain protein synthesis in CTL allowing IL-2 to act as a potent ‘growth factor’ for 
immune activated T cells (12, 24, 25). The ability to control protein synthesis (24, 25) 
allows IL-2 to modify the proteome of CTLs independently of the transcriptional 
program. One example of this is IL-2 control of the expression of the transcription 
factor MYC, where the dominant role of IL-2 is to regulate the synthesis of MYC 
protein independently of its mRNA (19). Furthermore, IL-2-regulation of mTORC1, 
which can control mRNA translation and cellular protein degradation pathways (23), 
is another means by which IL-2 may regulate cellular proteomes independently of 
transcriptional programs. 
 
The direct action of IL-2 is to activate JAK kinases, but understanding the full 
consequences of how IL-2 controls T cell function requires IL-2-dependent proteomes 
to be mapped. Accordingly, we have used high resolution quantitative mass 
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spectrometry to analyze how IL-2 regulates the CTL proteome to generate global and 
in-depth insights into how this key cytokine controls CD8+ T cell identity and controls 
cell cycle progression, metabolism and expression of effector molecules.  
 
Results 
IL-2 regulation of the CTL proteome 
To explore the role of IL-2 on effector CD8+ cytotoxic T lymphocyte (CTL) function, 
we used IL-2 differentiated effector CD8+ T cells from P14 TCR transgenic mice. 
IL-2 maintained CTL are large granular cells (Fig. 1A) that depend on IL-2 for 
sustained proliferation and viability. After 24 hours of IL-2 deprivation, CTL had 
similar viability to the IL-2 maintained cultures (Fig. 1A), but were decreased in size, 
as judged by flow cytometry forward scatter (Fig. 1A). After 48 hours of IL-2 
deprivation, cell viability had substantially decreased. The decrease in cell size of 
IL-2 deprived CTL observed by flow cytometry at the 24 hour time point (Fig. 1A) 
correlated with a reduction in CTL mass (Fig. 1B). Thus, to understand how IL-2 
shapes the CTL phenotype, we used quantitative label-free high-resolution mass 
spectrometry to compare the proteome of CTL maintained in IL-2 and CTL deprived 
of IL-2 for 24 hours. For these experiments, CTL were lysed in urea and digested with 
LysC and trypsin. Peptides were fractionated using strong anion exchange (SAX) 
chromatography before analysis with an LTQ-Orbitrap Velos mass spectrometer. 
MaxQuant was used to identify and quantify proteins (Supplementary Fig. S1A).  
 
Over 6200 protein groups were identified per biological replicate (Supplementary Fig. 
S1B- S1C and Supplementary Table S1) and there was >90% overlap in the proteins 
identified between the 3 biological replicates (Supplementary Fig. S1B-S1C). We 
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converted our label-free data into protein copy numbers per cell using “histone-ruler” 
methodology (26). The correlation between estimated copy numbers of proteins in 
different biological replicates of each condition was good, with the lowest r2-value 
being 0.90 (Supplementary Fig. S1D-S1E).  
 
IL-2 deprived CTL decreased in size (Fig. 1A) and mass (Fig. 1B) compared to IL-2 
maintained CTL. Hence a key question was whether IL-2 removal resulted in an equal 
and uniform reduction in all proteins in CTL. In total, ~6500 proteins were identified 
in both IL-2 maintained CTL and IL-2-deprived CTL (Fig. 1C) with protein 
expression spanning several orders of magnitude. A key result was that ~3000 
proteins were not significantly affected by the loss of IL-2: this included cytoskeletal 
and structural proteins, such as b-actin (ACTB), one of the most highly abundant 
proteins in CTL, vimentin and laminin-b and signaling molecules, such as PTPN6 
(SHP-1), PTPN22 and RAP1B (Supplementary Table S1). A further indication that 
loss of IL-2 signals did not result in a universal loss in protein was that the expression 
of a few proteins significantly increased by IL-2 deprivation (Fig. 1C).  
 
Approximately 100 proteins, including ribosomal proteins, glycolytic enzymes and 
the cytolytic effector molecules, Granzyme A and Granzyme B, contributed to ~50% 
of the mass of IL-2 maintained CTL (Fig. 1D). Therefore, IL-2 could control cell 
mass by regulating only the expression of abundant proteins. The overall reduction in 
mass of a CTL deprived of IL-2 was between 1.5-2-fold (Fig. 1B), and while this 
included the loss of some of the abundant proteins, the impact of IL-2 deprivation on 
the CTL proteome was complex. We found ~900 proteins that decreased 
proportionally to the overall loss in mass, indicative of some general cell scaling 
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down of protein content. However, the majority of IL-2 regulated proteins were 
changed in expression by more than 2-fold (Fig. 1C and Supplementary Table S2). 
The expression of a subset of CTL proteins was also highly sensitive to IL-2 
deprivation; there was a complete loss of ~140 proteins, and changes in expression of 
other proteins of >20-fold. The effect of IL-2 on CTL cell mass is, thus, not just a 
simple reduction and scaling down in overall cellular protein content, but a more 
complex reshaping of the proteome. 
 
Dominant effects of IL-2 on the CTL proteome  
To understand the most dominant consequences of IL-2 deprivation on the CTL 
proteome, we focused on the proteins that were most decreased by loss of IL-2. 
Approximately 140 proteins were only reproducibly identified in IL-2 maintained 
CTL: these proteins included the effector cytokines, lymphotoxin a (LT-a), and IFNg 
(Supplementary Table S2). Interestingly, TNFRSF9 (CD137 or 4-1BB) is one of the 
most down regulated proteins in CTL deprived of IL-2, going from ~300, 000 
molecules per cell in IL-2 maintained CTL to ~2000 molecules per cell in the absence 
of IL-2 (Supplementary Table S2). Other examples of cell surface receptors strongly 
regulated by IL-2 include the IL-4R, IL-12b1 and the inhibitory receptor, Tim-3 
(HAVCR2) (Fig. 1E). Previous studies have shown that the expression of the IL-2Ra 
(CD25) is controlled by IL-2 (27) and we identified a 2-5-fold reduction in the 
expression of IL-2Ra (CD25) following IL-2 deprivation of CTL (Fig. 1F). This 
decrease was consistent with the observed changes to CD25 as determined by flow 
cytometry analysis of the CTL prior to their proteomic analysis (Fig. 1G). We also 
noted that IL-2Rb and IL-2Rg, the other components of the IL-2 receptor, were 
decreased in IL-2 deprived CTL (Fig. 1E). Collectively, the proteomic data 
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highlighted the key role for IL-2 in sustaining the expression of proteins that allow 
CTL to respond to exogenous cytokines and inhibitory receptor stimuli. 
 
IL-2 regulation of cell cycle machinery  
A quintessential biological function of IL-2 is to control the clonal expansion of 
antigen receptor-activated T cells. The commitment of T cells to DNA synthesis is 
known to be dependent on the activity of cyclin D-CDK2 or cyclin D-CDK4 
complexes. Our data allowed us to quantitate the impact of IL-2 deprivation on the 
numbers and stoichiometry of the key cell cycle regulators to fully understand how 
IL-2 regulates T cell proliferation. We found that IL-2 positively regulated the 
expression of cyclin D2 (Fig. 1H) and cyclin D3 (Fig. 1I). Conversely, IL-2 
suppressed expression of the CDK inhibitor CDKN1B (p27kip) (Fig. 1J). In terms of 
copy numbers per cell, IL-2 deprived CTL showed increased levels of CDKN1B 
molecules relative to the numbers of cyclins D2 and D3 molecules (Fig 1K). This 
would result in decreased levels of active cyclin D/CDK complexes and would be 
consistent with inhibition of G1/S cell cycle progression. However, our data also 
revealed that IL-2 deprivation caused a decrease in expression of essential 
components of the DNA replication machinery (Fig. 1L) which would further impact 
on the ability of CTL to perform DNA synthesis. Another interesting insight from our 
data was that IL-2 sustained the expression of DNA damage repair proteins (Fig. 1L). 
As CDK4/6-cyclin D complexes can control the activity of E2F and the synthesis of 
DNA replication proteins (28), it could be that loss of the core DNA synthesis 
machinery is a consequence of loss of CDK4/6-cyclin D activity. There are, thus, 
multiple mechanisms by which loss of IL-2 signals influence DNA synthesis and 
repair in effector T cells to control T cell cycle progression and proliferation.  
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IL-2 regulation of the CTL cytolytic machinery 
The key cytolytic effector molecules of CTL are perforin, granzymes, and FAS ligand 
which are stored in granules which are specialized secretory lysosomes marked by 
expression of LAMP-1 (CD107a) and LAMP-2 (29). IL-2 only had a minor effect on 
LAMP1/2 expression in CTL, indicating that IL-2 loss did not significantly decrease 
the lysosomal content of the CTL (Fig. 2A-2B). However, IL-2 did influence the 
expression of cytolytic granule cargo molecules, notably perforin, but also granzyme 
A and B (Fig. 2C-2E). IL-2 also regulated expression of some essential regulators of 
cytolytic granule fusion with the plasma membrane such as RAB27A, STXBP2 
(MUNC18-2) and UNC13D (MUNC13-4) (Fig. 2F-2H). IL-2, thus, has the potential 
to regulate the protein content and release of lytic granules. 
 
IL-2 control of transcriptional regulators and core protein synthesis machinery 
Another key function of IL-2 is to regulate and maintain T cell transcriptional 
programs, in part via regulation of STAT5. Our data showed that IL-2 could have a 
significant influence on gene transcription, and hence mRNA production, in CTL by 
controlling the expression of multiple transcription factors (Fig. 3A). Moreover, 
histone and DNA methylases, DNA and RNA helicases and RNA processing proteins 
were all decreased in CTL in the absence of IL-2 (Fig. 3A). Indeed, some abundant 
transcription factors were potently regulated by IL-2 (Fig. 3A and Supplementary 
Table S2). These included ETS translocation variant 3 (ETVS3), MAFK, NFIL3 AP-
1 family proteins JUN, JUNB, JUND and FOSL2 (Fig. 3A). IL-2 also controlled 
Eomesodermin (EOMES), IRF8 and TCF25 expression (Fig. 3B). However, the 
expression of two crucial T cell transcription factors FOXO1 (Fig. 3C) and TBET 
(Fig. 3C) were not significantly changed by loss of IL-2 signals. These data highlight 
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that the ability of IL-2 to control gene transcription and the production and stability of 
mRNAs in T cells goes beyond control of STAT5 phosphorylation and activity.  
  
The phenotype of a cell is controlled by its transcriptional program but gene 
expression cannot be executed without protein synthesis. It has been shown that IL-2 
has a key role in regulating rates of protein synthesis in CD8+ T cells (24, 25) but the 
molecular basis for this is not understood. The proteomic analysis revealed that IL-2 
influenced protein synthesis on many levels. IL-2 controlled the expression of 
ribosomal proteins (Fig. 3D and 3E). In terms of ribosome copy number, CTL express 
~2.8 ´ 106 ribosomes and this reduces to ~1.2 ´ 106 ribosomes in IL-2 deprived cells. 
IL-2 also controlled expression of tRNA synthases, including the methionyl-tRNA 
synthase (Fig. 3E) and sustained the expression of critical components of the EIF 
translational initiation complex (Fig. 3E). Interestingly, IL-2 supported expression of 
proteins that regulate the transport of newly synthesized proteins into the ER and 
controlled expression of molecules that control protein folding and pathways of 
protein degradation in the ER lumen (Fig. 3E). These data reveal that IL-2 co-
ordinates expression of ribosomes, translation complexes and protein quality control 
pathways.  
 
IL-2 regulation of amino acid transporters and amino acid sensors 
A maintained supply of amino acids is required in order for cells to sustain high rates 
of protein synthesis. We have previously shown that IL-2 controls System L mediated 
amino acid transport in CTL (30). Moreover, CD8+ T cells that lack expression of the 
system L amino acid transporter SLC7A5 fail to differentiate into CTL (30). Our 
proteomics data showed that SLC7A5 is the most abundant amino acid transporter in 
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CTL expressed at ~170 000 copies per cell and that its expression was dependent on 
IL-2 (Fig. 4A). We also identified and quantitated expression of ~10 other amino acid 
transporters in CTL including transporters for arginine (SLC7A1) (Fig. 4B) and 
glutamine and serine (SLC1A5) (Fig. 4C). Strikingly, the expression of amino acid 
transporters was controlled by IL-2 (Fig. 4D). It was also of note that IL-2 regulated 
the expression of proteins required for amino acid biosynthesis (Fig. 4E) and the 
recovery of amino acids by autophagy (Fig. 4F- 4I). IL-2, thus, controls the supply of 
amino acids to CTL by multiple mechanisms. 
 
A source of amino acids is vital for the protein biosynthetic capacity of T cells, but 
also controls other essential metabolic processes. For example, serine fuels the 
biosynthesis of purine nucleotides needed for T cell proliferation (31); glutamine fuels 
critical protein O-GlcNAcylations in T cells (32); intracellular levels of arginine 
control the metabolic fitness and survival of T cells (33) and, together with leucine, 
regulate the activity of mTORC1. Signals mediated by mTORC1 are critical for 
controlling the differentiation of CD8+ T cells (20-22). The ability of IL-2 to control 
the supply of leucine and arginine affords insights as to how IL-2 can sustain high 
level of mTORC1 activity in effector CTL. However, other new insights are that IL-2 
controls the expression of amino acid sensing and regulatory proteins that direct 
mTORC1 activity (34) (Fig. 4J-4L). IL-2, hence, drives expression of the cytosolic 
leucine sensor SESTRIN2 (Fig. 4K) and the GTPase RHEB (Fig. 4L). IL-2, thus, 
regulates amino acid-dependent activation of mTORC1 in two ways; by regulating the 
supply of amino acids and by controlling the abundance of amino acid-sensing 
pathways. 
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IL-2 control of glucose metabolism and oxygen sensing 
CTL have high rates of glucose transport, are highly glycolytic and have high rates of 
oxidative phosphorylation and need to sustain these metabolic programs for effector 
function (23). In our dataset, we found that proteins mapped to oxidative 
phosphorylation comprised ~1% of the IL-2-maintained CTL proteome by mass (Fig. 
5A), proteins of the TCA cycle were ~0.8% of the CTL proteome (Fig. 5B), and ~9% 
of the CTL proteome consisted of glycolytic enzymes (Fig. 5C). IL-2 deprivation did 
scale down the proteins involved glucose metabolism but they remained highly 
expressed and at a similar relative abundance (Fig. 5A-5C). However, the rate 
limiting step for glucose metabolism in CTL is glucose transport, and our data 
demonstrated that IL-2 controls expression of the glucose transporters GLUT1 
(SLC2A1) and GLUT3 (SLC2A3) in CTL (Fig. 5D-5E). The relevance of the changes 
in glucose transporter expression is evidenced by the decrease in the glucose transport 
capacity of IL-2 deprived CTL compared to CTL maintained in IL-2 (Fig. 5F).  
 
The expression of glucose transporters in CTL is controlled by the HIF1a/HIF1b 
transcriptional complex (21). IL-2 deprivation caused a decreased expression of 
HIF1b (Fig. 5G) and HIF1a (Fig. 5H) (21). We have previously described HIF1 
target genes in CTL (21) and our data showed that in addition to the loss of GLUT1 
and GLUT3, other transcriptional targets for HIF1, such as perforin (Fig. 2C), the 
inhibitory receptor, Tim-3 (HAVCR2) (Fig. 5I) and NFIL3 (Fig. 5J) were decreased 
upon IL-2 deprivation. Additionally, we have previously established that HIF1 
complexes repress expression of the cell adhesion molecule, CD62L (L-selectin) (21). 
The increased expression of CD62L (Fig. 5K) in IL-2 deprived CTL was thus also 
consistent with the loss of the HIF transcriptional program.  
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In CTL, the expression of HIF1a is promoted by the activity of the mTORC1 
pathway (21). In the presence of high oxygen, the oxygen-dependent proline 
hydroxylase (PHD) proteins hydroxylate prolines within HIF1a, targeting HIF1a for 
ubiquitination by the VHL ubiquitin ligase. This limits the levels of HIF1a in CTL 
when oxygen levels are high but allows very tight upregulation of HIF1a expression 
in response to changes in the oxygen environment. The importance these oxygen 
sensing pathways mediated by PHD proteins and VHL in restraining CD8+ T cell 
immune responses is being increasingly recognized (35). We identified PHD2 as the 
dominant proline hydroxylase in CTL and did not detect PHD1 or PHD3. The 
expression of PHD2 was IL-2-regulated (Fig. 5L), highlighting IL-2 is a critical 
regulator of oxygen sensing signaling pathways in CTL.  
 
IL-2 controls the CTL proteome via JAK kinases 
IL-2-induced activation of JAK1 and JAK3 are essential for IL-2 signal transduction. 
Accordingly, a prediction is that pharmacological inhibition of JAKs would mimic the 
effect of IL-2 deprivation and re-shape the CTL proteome. We tested this prediction 
by using mass spectrometry to compare the proteome of CTL maintained in IL-2 
alone or IL-2 in the presence of the JAK1/3 inhibitor, Tofacitinib, which is now used 
clinically to modify JAK1/3 activity in autoimmune diseases. In these experiments, 
we treated CTL with 100 nM of Tofacitinib, within the range of Tofacitinib levels 
found in plasma when this drug is used therapeutically (36-39). Moreover, 100 nM 
Tofacitinib is sufficient to downregulate the tyrosine phosphorylation of STAT5 in 
CTL (Fig. 6A) (24) and is sufficient to prevent T cell cycle progression (Fig. 6B), 
suppress protein synthesis (24) and decrease the size (Fig. 6C) and protein content of 
CTL (Fig. 6D). Importantly, T cells treated with 100 nM Tofacitinib are viable after 
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24 hours of treatment; higher levels of the drug cause losses in cell viability. In the 
experiments with Tofacitinib, ~7000 protein groups were identified in the IL-2 
maintained control and Tofacitinib treated CTL (Supplementary Fig. S2A-S2B and 
Supplementary Table S3). In each of these datasets, there was good correlation and 
over 87% overlap in the identified proteins between the replicates of each condition 
(Supplementary Fig. S2A-S2D). Inhibition of the JAK kinases had a less dramatic 
effect on the CTL proteome than IL-2 deprivation, but Tofacitinib treatment mirrored 
multiple aspects of the effect of IL-2 deprivation on the CTL proteome. For example, 
JAK1/3 inhibition caused loss of the cell surface proteins CD25 (Fig. 6F-6G), IL-
4Rα, IL-12Rβ1 and TNFRSF9 (4-1BB/CD137) (Fig. 6E).  
 
The expression of key cell cycle regulatory proteins and DNA synthesis machinery 
was also controlled by JAK1/3 (Fig. 7A). Tofacitinib treatment also replicated the 
effect of IL-2 removal on protein synthesis machinery and regulated proteins involved 
in ribosome biosynthesis and caused a reduction in the ribosome proteins (Fig. 7A). 
Inhibition of JAK1/3 mimicked the effect of IL-2 deprivation on the expression of 
amino acid transporters (Fig. 7B) and, like IL-2 deprivation, CTL treated with 
Tofacitinib decreased the expression of the mTORC1 pathway leucine sensor, Sestrin-
2 (Fig. 7C). Tofacitinib treatment of CTL also decreased expression of the HIF1 
targets, GLUT1 and GLUT3 (Fig. 7D-7E). This correlated with Tofacitinib-treated 
CTL having reduced glucose uptake (Fig. 7F) and glycolysis, as judged by lactate 
output (Fig. 7G) compared to IL-2 maintained CTL. Tofacitinib treated CTL also lost 
expression of other HIF targets such as perforin (Fig. 7H) and the NFIL3 transcription 
factor (Fig. 7I). This dependency of HIF1a expression on JAK activity was confirmed 
by immunoblot analysis with selective HIF1a antibodies (Fig. 7J). Collectively, these 
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data highlight how the ability of IL-2 to shape the T cell proteome is dependent on 
JAK catalytic activity; the data also give pertinent information about the extent to 
which a clinically relevant inhibitor of JAK signaling modulates T cell responses to 
IL-2.  
 
New insights about oxygen sensing pathways and the control of CTL 
transcriptional programs 
A challenge with large, unbiased datasets is identifying data that give genuine new 
biological insights. In the current study, one strategy was to focus on molecules that 
had the largest change in protein expression in IL-2 deprived or Tofacitinib treated 
CTL. Another filter was to focus on molecules identified previously by our 
experiments mapping critical signaling pathways mediated by mTORC1 and HIF1 
complexes in CTL (21, 23). If these two filters were applied, then the transcriptional 
factor NFIL3 emerged as major target for IL-2-JAK1/3-mTORC1-HIF1 signaling. 
Our proteomics data, thus, indicated that NFIL3 was dramatically decreased in copy 
number (Fig. 5J and 7I) and relative abundance (Fig. 8A) in CTL in response to IL-2 
deprivation or Tofacitinib treatment. These results were orthogonally validated by 
western blot analysis, showing that NFIL3 was lost in response to IL-2 deprivation or 
Tofacitinib treatment (Fig. 8B). IL-2 deprivation and Tofacitinib treatment also 
decreased the relative amount of NFIL3 mRNA (Fig. 8C), suggesting transcriptional 
regulation of NFIL3 contributes to its sustained expression in IL-2 maintained CTL.  
 
NFIL3 has critical functions in NK cells (40), CD4+ T cells (41) and innate lymphoid 
cells (ILC) (42) but has not been previously reported to be expressed in CD8+ T cells. 
Therefore, we evaluated the expression levels of NFIL3 at the protein and transcript 
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level in naïve and antigen activated P14 CD8+ T cells. We found that NFIL3 protein 
and mRNA was undetectable in naïve CD8+ T cells (Fig. 8D-8E) and low, albeit 
detectable, in antigen receptor activated T cells (Fig. 8D-8E). However, when antigen 
activated CD8+ T cells were clonally expanded in IL-2 to produced effector CTL the 
levels of NFIL3 mRNA and protein increased and were sustained at high levels (Fig. 
8D-8E). This is consistent with the model that NFIL3 expression is not TCR regulated 
but is dependent on IL-2-JAK1/3 signaling. Our proteomic data indicated that the 
expression of NFIL3 expression is dependent on mTORC1 activity (23). We, thus, 
used immunoblot analysis and validated that the expression of NFIL3 in IL-2 
maintained CTL is dependent on JAK1/3 signaling and mTORC1 signaling (Fig. 8F).  
 
What about the role of oxygen sensing pathways in the control of NFIL3 expression? 
Affymetrix microarray analysis found that NFIL3 mRNA was decreased in HIF1b 
null CTL (21). We, thus, evaluated NFIL3 levels in HIF1α null (HIF1α-/-) CTL. We 
found that NFIL3 expression in effector CTL was absolutely dependent on HIF1α 
expression (Fig. 8G). We also explored whether NFIL3 expression was increased if T 
cells were switched from 20% oxygen to 1% oxygen as this is known to increase 
expression of HIF1α and its target genes, including the glucose transporter GLUT1 
(SLC2A1) and perforin (21). We found that NFIL3 protein expression increased when 
wild-type but not HIF1α-/- CTL were switched from 20% oxygen to 1% O2 (Fig. 8G). 
This correlates with an increase in NFIL3 mRNA in CTL cultured in 1% O2 
compared to CTL cultured in 20% O2 (Fig. 8H). This effect is comparable to the 
effect of the oxygen switch on expression of GLUT1 (Fig. 8I). Collectively, these 
data show that the expression of NFIL3 in CTL is regulated by oxygen sensing 
pathways controlled by the HIF1 transcription factor complex.  
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Is this regulation of NFIL3 in CTL important? To explore this question, CD8+ naïve T 
cells from the spleens of NFIL3-/- deficient mice were TCR activated and clonally 
expanded in IL-2. NFIL3-/- CD8+ T cells activated normally in response to TCR, and 
proliferated in response to IL-2 (Supplementary Fig. S3A). Moreover, IL-2 
maintained NFIL3-/- CD8+ effector T cells had normal levels of IL-2Ra and activation 
markers such as CD25, CD69 and CD44 (Supplementary Fig. S3B-S3D). They also 
showed normal activity of AKT and mTORC1, key regulators of CTL differentiation 
(Supplementary Fig. S3E-S3F). We have previously reported that HIF1 null effector 
CD8+ T cells fail to downregulate expression of CD62L, a key adhesion molecule that 
controls lymphocyte migration into secondary lymphoid tissue, and do not express 
perforin (21). NFIL3-/- CD8+ T cells phenocopied HIF1a null CD8+ T cells and 
retained high levels of expression of CD62L mRNA and protein (Fig. 8J-8K) and 
failed to express perforin mRNA and protein (Fig. 8L-8M). Collectively, these data 
identify NFIL3 as a transcription factor whose expression is regulated by mTORC1 
and HIF1-mediated oxygen sensing pathways. They also show that NFIL3 controls 
perforin expression in T cells and has a role to repress expression of CD62L in 
immune activated CD8+ T cells. 
 
Discussion 
The present study provides an in-depth understanding of how the proteome of effector 
CD8+ T cells can be shaped by IL-2-JAK1/3 signaling. Our data uncover novel 
insights into the IL-2 regulated cellular processes and proteins that control 
differentiation and function of these key effector cells. One key perspective from the 
proteomic analysis was the extent to which IL-2-JAK1/3 signaling controls the ability 
of effector T cells to respond to their immune environment. IL-2 controls expression 
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of multiple cell surface molecules including receptors for the cytokines IL-4 and IL-
12, the inhibitory receptor, Tim-3 (HAVCR2) and the co-stimulatory receptor, 4-1BB. 
The signaling pathways controlled by these receptors can modulate T cell responses 
powerfully. Indeed, a 4-1BB agonist antibody, Utomilumab, is in clinical trials to 
promote effector CD8+ anti-tumor T cell therapy. The recognition that the expression 
of 4-1BB is tightly regulated by IL-2 is a useful insight into how therapeutic IL-2 
treatments may be able to boost the function of effector T cells.  
 
A further insight from our data was that IL-2 maintains the expression of proteins that 
stimulate the differentiation and pro-inflammatory actions of CTL in parallel with 
those that may keep these activities in check, thus potentially maintaining cellular 
fitness. IL-2 induces a pro-inflammatory gene expression program by regulating the 
activity of transcription factors such as STAT5, HIF1a and NFIL3 and by boosting 
protein synthesis. IL-2 stimulates the production of proteins on many levels by 
regulating levels of amino acid transporters, tRNA synthases, ribosomal subunits, 
core translational machinery and proteins that coordinate the assembly of 
translationally competent ribosomal complexes This allows IL-2 to modulate cell 
phenotype independently of transcriptional networks. Yet, our data revealed that IL-2 
equally sustained the expression of proteins that destroy mis-folded proteins. 
Maintaining these protein degradation pathways may be required to prevent the 
accumulation of damaged proteins and preserve the cellular fitness of these CTL as 
they perform the high rates of protein biosynthesis required for rapid cell proliferation 
and effector function. In a similar way, IL-2 finely tunes the expression of proteins to 
prevent aberrant immune responses. For example, IL-2 stimulated the expression of 4-
1BB, which boosts CTL function, but also regulated the expression of Tim-3 
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(HAVCR2), which can inhibit CTL function. The ability of IL-2 to control expression 
of stimulatory and inhibitory receptors would, therefore, control the balanced activity 
of effector T cells. 
 
One fundamental insight from the current data set is the dominant role for IL-2 in 
controlling how effector T cells respond to their nutrient environment. We found that 
IL-2 regulated a diverse repertoire of nutrient transporters including those required for 
uptake of glucose, iron, methionine, leucine, serine, arginine and glutamine. These 
amino acids are necessary for protein synthesis and for other critical metabolic 
pathways. IL-2 also maintained the expression the amino acid sensing pathways 
mediated by the leucine sensor Sestrin-2 that controls mTORC1 activity. The 
importance of nutrient supply for effector T cell function is now well recognized, and 
the effects of IL-2 on nutrient transporter expression, therefore, allow IL-2 to have a 
major role in co-regulating metabolism and protein expression in effector CD8+ T 
cells.  
 
One other important discovery was the integration of IL-2 signaling and oxygen 
sensing signaling pathways. The importance of oxygen sensing in regulating effector 
T cell function is increasingly recognized. The HIF1 signaling pathway is a crucial 
regulator of T cell differentiation, and controls the expression of glucose transporters, 
glycolytic enzymes, chemokine receptors, adhesion molecules and the cytolytic 
effector molecule, perforin (21, 43). Indeed, elevated HIF1a expression has been 
linked to enhanced effector CD8+ T cell function (43) and loss of PHD protein 
expression improves the efficacy of effector T cells in the lung to clear tumor 
metastases (35). The expression of PHDs in T cells in the lung also suppresses 
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effector T cells to prevent immune-mediated tissue damage (35). Therefore, it is 
important to understand that IL-2 drives the expression of both HIF1a and PHD2. 
 
In this respect, another novel and intriguing discovery from this study was the 
convergence of IL-2 and oxygen sensing signaling pathways. An example of this was 
IL-2 and HIF1 control of the expression of NFIL3, a bZIP family transcriptional 
repressor in CTL. Previous studies have shown that NFIL3 is important for the 
development of both NK (40) cells and ILC (42). Our finding that NFIL3 is regulated 
by HIF1 downstream of IL-2 and hypoxia reveals a novel insight into how the 
expression of this important transcription factor is controlled. It is noteworthy that we 
found that NFIL3 expression in CTL was strongly downregulated in response to the 
JAK1/3 inhibitor Tofacitinib. This inhibitor is in clinical use, and our data, thus, gives 
intriguing insights into the molecular details of how these drugs control immune cell 
function: for example, it could be important to understand if JAK kinase mediated 
control of oxygen sensing and HIF1 transcription factors determines NFIL3 
expression in NK cells or ILCs.  
 
In summary, the current data highlight the multiple ways in which IL-2/JAK signaling 
can shape the proteomic landscape of effector T cells to control protein metabolism 
and other key cellular metabolic programs. These data offer a comprehensive 
understanding of the impact of IL-2 signaling on effector T cells that explain the 
powerful immunomodulatory actions of this cytokine.  
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Materials and Methods 
Study plan 
This study aimed to define the proteome of in vitro generated CTL in the presence or 
absence of IL-2 and the JAK kinase inhibitor, Tofacitinib. Three biological replicates 
were used for proteomic studies	 Each biological replicate was generated from the 
spleen of one mouse. Mice were age-matched and sex-matched, and were used 
between 12-15 weeks of age. Where possible, cage-mates were used within each 
experiment. Other experiments were performed as indicated in the figure legends. 
 
Mice 
P14 mice have been described previously (44). Female P14 T cell receptor transgenic 
mice were used for proteomic studies, and both male and female mice were used for 
other experiments. Mice with floxed Hif1a alleles were crossed with mice expressing 
Cre recombinase under the control of the Vav promoter to generate mice with deletion 
of HIF1α in Vav expressing cells. NFIL3-/- mice have been described previously (40). 
All mice were bred and maintained in compliance with UK Home Office Animals 
(Scientific Procedures) Act 1986 guidelines. 
 
In vitro cultures of Cytotoxic T Lymphocytes (CTL) 
Cytotoxic T Lymphocytes (CTL) were generated as described previously (24). 
Briefly, CD8+ naïve T cells taken from the spleens of mice were activated by 
triggering of the T cell receptor (TCR) for 48 hours in the presence of 20 ng/ml IL-2 
(Proleukin, Novartis) and 2 ng/ml IL-12 (R and D Systems). P14 mice were activated 
using 100 ng/ml gp-33 peptide of the Lymphocytic Choriomeningitis Virus (LCMV) 
 22 
and TCR non-transgenic T cells were activated using 0.5µg/ml α-CD3 (BioLegend) 
and 0.5µg/ml α-CD28 (eBioscience). 
 
After 48 hours of antigen activation, the activated CD8+ cells were removed from 
TCR stimulation and were then cultured in RPMI 1640 (Life Technologies), with 
10% fetal bovine serum (FBS) (Life Technologies), supplemented with 50 units/ml 
penicillin-G (GIBCO), 50 µg/ml streptomycin (GIBCO), 50 µM β-mercaptoethanol 
(Sigma-Aldrich) and 20 ng/ml IL-2 (Proleukin, Novartis). CTL were differentiated in 
IL-2 for 4 days before any 24 hour treatments were performed. Samples were 
considered biological replicates if CTL were generated from separate spleens. 
 
When required, CD8+ T cells were purified and isolated using the EasySep™ Mouse 
CD8+ isolation kit (STEMCELL Technologies) as directed by the manufacturer’s 
instructions.  
 
Inhibitors and cell treatments 
Cells were treated with 100 nM Tofacitinib (from Selleckchem, Munich, Germany). 
Where appropriate, cells were treated with DMSO as controls. To deprive cells of 
IL-2, cells were pelleted, washed in an excess of pre-warmed media lacking IL-2 for 5 
minutes before being pelleted and resuspended in pre-warmed media lacking IL-2. 
For the IL-2 maintained controls, the CTL were subjected to the same washes with 20 
ng/ml IL-2 being added back before further culturing. 
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Proteomic sample processing 
Following CTL generation and treatment, CTL were lysed in urea buffer (8 M urea, 
50 mM Tris pH 8.0, 1 mM TCEP) with protease (cOmplete™ mini EDTA free, 
Roche) and phosphatase inhibitors (PhosStop, Roche) at room temperature for 30 
minutes. Samples were sonicated, and protein concentration was determined using a 
BCA assay according to the manufacturer’s instructions (Pearce). To reduce samples, 
10 mM DTT was added for 30 minutes at room temperature. Following reduction, 50 
mM iodoacetimide was added to each sample and incubated for 45 minutes at room 
temperature in the dark. Samples were then diluted to 4 M urea with 100 mM Tris pH 
8.0/1 mM CaCl2. LysC (Wako), reconstituted in 100 mM Tris pH 8.0/1 mM CaCl2, 
was then added to each sample at a ratio of 50:1 protein:LysC and samples incubated 
with LysC overnight at 30°C. Samples were then transferred to low bind 15 ml falcon 
tubes (Eppendorf) and further diluted with 100 mM Tris pH 8.0/1 mM CaCl2 to 0.8M 
urea. Trypsin (Promega), reconstituted with 100 mM Tris pH 8.0/1 mM CaCl2, was 
then added to samples at a ratio of 50:1 protein:trypsin, and samples incubated for 8 
hours at 30°C. Following digestion, samples were desalted using C18 SepPack 
cartridges (Waters) and dried down in a SpeedVac (Genevac). 
 
Dried down peptide samples were resuspended 10 mM sodium borate 20% (v/v) 
acetonitrile, pH 9.3 and fractionated into 16 fractions by strong anion exchange 
(SAX) chromatography. Fractions were desalted and dried and then resuspended in 
1% formic acid and separated by nanoscale C18 reverse phase chromatography 
(Ultimate 3000 RSLC nano system, Thermo Scientific) before being electrosprayed 
into the Linear Trap Quadrupole-Orbitrap mass spectrometer (LTQ-Orbitrap Velos 
Pro; Thermo Scientific). Mass spectrometry was performed by the Proteomics 
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facility, University of Dundee, UK. Full details of SAX chromatography and LC-MS 
are in Supplementary Materials and Methods. 
 
Proteomic data processing and analysis 
The mass spectrometry data files were processed using MaxQuant version 1.6.0.1 and 
spectra were mapped to the reviewed UniProtKB mouse protein database and the 
contaminant database supplied by MaxQuant. Full parameters can be found in 
Supplemental Materials and Methods. Following processing of the files by 
MaxQuant, Perseus software implementing the proteome ruler plug-in was used to 
calculate estimated copy numbers of proteins per cell. This analysis assigns the copy 
numbers of histones in a diploid mouse cell to the summed peptide intensities of all 
histones in a sample in order to estimate copy numbers for all identified proteins in 
the dataset (26). The accuracies of the quantification were annotated based according 
to the number of peptides and % unique peptides identified for the protein as follows: 
high: ≥8 peptides detected, minimum of 75% unique peptides; medium: ≥3 peptides 
detected, a minimum of 50% unique peptides; low: all other peptides. 
 
Data quality was assessed by evaluating peptide intensities for normal distribution, 
the overlap in protein identification and the correlation of the estimated copy number 
between replicates. The output from MaxQuant was filtered to remove known 
contaminants, the proteins identified as part of a reversed protein library, and proteins 
identified only by a modified site. To evaluate changes to the proteome resulting from 
loss of IL-2-JAK1/3 signaling, the estimated copy numbers were used to determine 
the ratio of expression of individual proteins within biological replicates. The 
significance of these changes was determined by performing a one-sample t-test, 
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without further adjustment, on the ratios of the treated condition:IL-2 maintained 
condition. Proteins were defined as significantly regulated if they had a ratio of ≥1.5 
or ≤ 0.67 and a P-value of ≤0.05. 
 
Western blotting 
Cells were lysed in RIPA buffer (50 mM Tris pH 7.4, 1% NP-40, 0.5% sodium 
deoxycholate, 0.1% SDS, 150 mM NaCl, 2mM EDTA, 50 mM NaF, 20 mM TCEP) 
with cOmplete™ mini EDTA free protease inhibitor tablets (Roche) for 10 minutes at 
4°C. The resulting lysates were sonicated, and then mixed with NuPAGE® LDS 
sample buffer supplemented with TCEP before being heated to 70°C for 10 minutes. 
Samples were separated on an SDS-PAGE gel using the Mini-PROTEAN Tetra Cell 
system. Following separation, proteins were transferred to nitrocellulose membranes 
(Hybond-C Extra, Amersham). Primary antibodies were detected using HRP-
conjugated secondary antibodies (goat anti rabbit, Thermo Scientific #31460; goat 
anti mouse, Thermo Scientific #31430), and chemiluminescence was detected using 
X-ray films (Konica) or an Odyssey Fc Imaging System (Licor). Primary antibodies 
can be found in Supplementary Materials and Methods. 
 
Cell staining and flow cytometry 
Cells were stained with saturating concentrations of the following antibodies: CD25 
(BD BioScience, clone PC61; or BD Pharmingen, clone 7D4,), CD69 (eBioscience, 
clone HI.2F3), CD44 (BD Pharmingen, clone IM7), CD62L (BD Pharmingen, MEL-
14), CD4 (eBioscience, clone RM4-5), CD8 (BioLegend, clone 53-6.7). Data were 
acquired on a FACS Verse flow cytometer with FACSuite software (BD Biosciences) 
or a FACS LSR Fortessa flow cytometer with DIVA software (BD Biosciences). 
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Viable cells were gated according to their forward- and side-scatter profiles. Data 
analysis was performed with FlowJo software (Treestar).  
 
RNA extraction and qPCR 
RNA was isolated using the Qiagen RNeasy kit and cDNA was generated using the 
Quantas cDNA synthesis kit. RT-PCR was performed with the SYBRgreen dye 
(BioRad) on a iCycler iQ™ PCR machine. TBP, CD8 and HPRT were used as the 
reference gene as indicated in the figure legend. Data were analyzed using the ΔΔCT 
method. Primers can be found in the Supplementary Materials and Methods.  
 
Glucose uptakes 
The measurement of radiolabelled glucose uptake has been described previously (21). 
Briefly, glucose free RMPI 1640 labelled with 0.5 µCi/ml radiolabelled 2-deoxy-d-[1-
3H]glucose (Perkin Elmer) was layered over 500µL of a 1:1 mixture of silicone oil 
(Sigma Aldrich) and dibutyl phthalate (Sigma Aldrich). Cells (1x106 per uptake) were 
added and allowed to take up radiolabelled 2-deoxy-d-[1-3H]glucose for 4 minutes. 
Cells were lysed in 100 mM NaOH and the radioactivity analyzed using a Beckman 
LS 6500 Multi-Purpose Scintillation Counter (Beckman Coulter). Assays were 
performed in duplicate or triplicate per biological replicate. For each biological 
replicate, data were normalized to the uptake of 2-deoxy-d-[1-3H]glucose in the IL-2 
maintained CTL sample. 
 
Lactate output 
Lactate measurements were performed as described (21). CTL were resuspended to a 
concentration of 2x106 cells/ml in RPMI with 10% (v/v) dialyzed serum and 
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incubated for 4 hours. Following incubation, the supernatants were collected. Lactate 
concentration was determined using an enzymatic assay in which the oxidation of 
lactate by lactate dehydrogenase (LDH) is monitored by the change in absorption at 
340 nM following reduction of NAD+ to NADH. To determine lactate concentration, 
equal volumes of supernatant and master mix (320 mM glycine, 320 mM hydrazine, 
2U lactate dehydrogenase and 2.4mM NAD+) were mixed and incubated for 10 
minutes at room temperature. Absorbance of the reactions was then read at 340 nM 
using a cytofluor II Fluorescence Multi-Well Plate Reader (Perceptive BioSystems). 
A lactate standard curve was generated and the concentration of lactate in the test 
samples inferred following data analysis in Prism (GraphPad). 
 
Statistical analyses 
Statistical analyses were performed as outlined in the proteomics methods section. 
 
Supplementary Materials 
Supplementary Materials and Methods 
Fig. S1: Proteomic analysis of CTL 
Fig. S2: Proteomic analysis of CTL treated with and without Tofacitinib 
Fig. S3: Activation and generation of CTL from NFIL3-/- T cells 
Table S1. The proteome of IL-2-maintained and IL-2 deprived CTL. 
Table S2. The IL-2 regulated proteome of CTL. 
Table S3. The proteome of IL-2-maintained CTL in the presence or absence of 
Tofacitinib. 
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Figures: 
Fig. 1 
 
Fig. 1: IL-2 regulation of the CTL proteome.  
(A) Size and viability of CTL maintained or deprived of IL-2 as judged by flow 
cytometry forward scatter (FSC) and side scatter (SSC). (B) Protein content of IL-2 
maintained and IL-2 deprived CTL. (C) The Venn diagram shows the commonality of 
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proteins identified in the proteomic analysis, and the volcano plot shows the ratio of 
the protein copy number in CTL deprived of IL-2 for 24 hours compared to IL-2-
maintained CTL. Proteins significantly changed (one sample students t-test P < 0.05) 
by greater that 1.5-fold are shown in red. The 2-fold downregulation cut-off is 
indicated by the dashed line. (D) Average protein mass frequency per cell - bins 
containing the proteins that make up ~50% of the total CTL mass are shown in black. 
(E) Volcano plot as in (C), with surface receptors shown in red. (F) Molecule 
numbers, estimated from the proteomic data, for the expression of IL-2Ra (CD25). 
(G) Flow cytometric analysis of CD25 cell surface expression. Copy numbers 
estimated from the proteomic data for Cyclin D2 (CCND2) (H), Cyclin D3 (CCDN3) 
(I), and p27 (CDKN1B) (J). (K) The ratio of p27 to the total sum of Cyclin D2 and 
Cyclin D3 molecules was calculated and plotted. (L) Schematic representation of 
selected cell cycle proteins, and DNA synthesis and repair enzymes regulated by IL-2. 
Data show, or are representative of, three biological replicates. In bar charts, data 
points from biological replicates are color matched, the bar shows the mean and the 
errors bars show standard deviation. 
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Fig. 2 
 
Fig. 2: IL-2 regulation of CTL cytolytic machinery  
Copy numbers estimated from the proteomic data for Lamp1 (A), Lamp2 (B), 
Perforin 1 (C), Granzyme A (D), Granzyme B (E), RAB27A (F), STXBP2 (G) and 
UNC13D (H). In graphs, the three biological replicates are color-matched, the bar 
shows the mean and errors bars show standard deviation.  
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Fig. 3 
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Fig. 3: IL-2 regulation of gene expression.  
(A) Schematic representation of selected transcription factors, DNA modifying 
enzymes and mRNA-binding proteins identified by mass spectrometry in CTL. 
Proteins downregulated by loss of IL-2 are highlighted in purple. Copy numbers 
estimated from the proteomic data for Eomesodermin (EOMES), IRF8, TC25 (B), 
and TBET (TBX21) and FOXO1 (C). (D) The number of ribosomes per cell was 
estimated by calculating the median copy number of all the proteins annotated with 
the KEGG pathway “ribosome” for each biological replicate and each condition and 
were plotted in a bar chart. (E) Schematic representation of selected proteins involved 
in ribosomal biogenesis, translation and protein processing in the endoplasmic 
reticulum. Proteins downregulated by loss of IL-2 are highlighted in purple. In graphs, 
individual data points from the three biological replicates performed for the proteomic 
analysis are shown and color matched, with the bar showing the mean and the errors 
bars showing standard deviation of the experiments.  
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Fig. 4 
 
Fig. 4: IL-2 regulation of amino acid uptake and biosynthesis and mTORC1. 
Copy numbers estimated from the proteomic data for the amino acid transporter 
SLC7A5 (A), SLC7A1 (B) and SLC1A5 (C). (D) and (E) Volcano plots of the IL-2-
dependent proteome: ratio of the protein abundance (copy number) in IL-2 deprived 
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CTL compared to IL-2-maintained CTL is plotted against P value (one sample 
students T-test). Proteins whose ratios are significantly regulated (P < 0.05) by greater 
that 1.5-fold are shown in dark grey, with amino acid transporters highlighted in red 
in (D) and proteins involved in amino acid biosynthesis in (E). Bar graphs (F-I) show 
estimated copy numbers calculated using the proteomic data for VPS34 (F), VPS15 
(G), ATG4B (H) and ATG5 (I). (J) Schematic representation of proteins involved in 
activation of mTORC1 signaling. Proteins downregulated by loss of IL-2 are 
highlighted in purple. Estimated copy numbers per cell for SESTRIN2 (K) and RHEB 
(L). In graphs (A-C, F-I and K-L), individual data points from the three biological 
replicates performed for the proteomic analysis are shown and color matched, with 
the bar showing the mean and the errors bars showing standard deviation of the 
experiments.  
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Fig. 5 
 
Fig. 5: IL-2 JAK1/3 regulation of cellular energy generation. 
(A-C) Graphs show the estimated mass of proteins annotated with the KEGG 
pathway terms “oxidative phosphorylation” (OxPhos) (A) “TCA cycle” (B) or 
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“glycolysis” (C) per cell in IL-2 maintained and IL-2 deprived CTL. Estimated mass 
per protein was determined using estimated copy numbers calculated from the 
proteomic data using the histone ruler method. The bar charts in (D-E), (G) and (I-L) 
show estimated copy numbers per cell for GLUT1 (SLC2A1) (D), GLUT3 (SLC2A3) 
(E), HIF1b (G), TIM-3 (I), NFIL3 (J), L-selectin (CD62L) (K) and PHD2 (L). (F) 
Glucose uptake in IL-2 maintained and IL-2 deprived CTL was measured using 
radiolabeled 2-deoxyglucose. (H) HIF1a expression in CTL in the presence and 
absence of IL-2 was measured by immunoblot (representative of at least 3 biological 
replicates). In bar charts, individual data points from the three biological replicates are 
shown and color matched, with the bar showing the mean and the errors bars showing 
standard deviation of the experiments.  
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Fig. 6 
 
Fig. 6: The impact of Tofacitinib on CTL. 
(A) Western blot of STAT5A/B phosphorylation in response to 100 nM Tofacitinib 
treatment. (B) Flow cytometric analysis of cell cycle stages using EdU incorporation 
into DNA. The percentage of CTL identified as in G1 and S are shown alongside. 
Flow cytometry profiles (C) and protein content (D) of IL-2 maintained CTL treated 
with or without Tofacitinib for 24 hours. (E) The Venn diagram shows the 
commonality of proteins identified in the proteomic analysis, and the volcano plot 
shows the ratio of the protein copy number in IL-2 maintained CTL treated with 100 
nM Tofacitinib for 24 hours compared to IL-2-maintained CTL is plotted against P 
value (one sample students t-test). Proteins whose ratios are significantly regulated (P 
< 0.05) by greater that 1.5-fold are shown in red. The regulation of IL-2Ra, IL-4Ra, 
4-1BB and IL-12Rb1 are annotated. CD25 expression as measured by the proteomic 
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data (F) and flow cytometry (G) with or without Tofacitinib for 24 hours. The data 
show, or are representative of, three biological replicates. In bar charts, data points 
from biological replicates are color matched, the bar shows the mean and the errors 
bars show standard deviation. 
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Fig. 7 
 
Fig. 7: The Tofacitinib-regulated CTL proteome. 
(A) Schematic representation of selected molecules regulated by Tofacitinib. (B) 
Volcano plot showing the protein copy number ratio in IL-2 maintained CTL treated 
with 100 nM Tofacitinib for 24 hours compared to IL-2-maintained CTL, 
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significantly regulated proteins are shown in dark grey and nutrient transporters are 
highlighted in red. Estimated copy numbers per cell are shown for SESTRIN2 (C), 
GLUT1 (D) and GLUT3 (E). (F) Uptake of a radiolabelled glucose analogue 
expressed relative to IL-2. (G) Lactate output in IL-2 maintained and Tofacitinib 
treated CTL. Estimated copy numbers per cell for perforin (H) and NFIL3 (I).  (J) 
Western blot analysis of HIF1a expression in response to 100 nM Tofacitinib. The 
data show, or are representative of, three biological replicates. In bar charts, data 
points from biological replicates are color matched, the bar shows the mean and the 
errors bars show standard deviation. 
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Fig. 8 
 
Fig. 8: Regulation of NFIL3 by IL-2-JAK1/3 signaling 
(A) Average frequency of protein copy numbers per cell calculated from the 
proteomic datasets: the bin that contains NFIL3 is indicated in black. (B) Western blot 
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analysis of NFIL3 protein expression in CTL following IL-2 deprivation or treatment 
with 100 nM Tofacitinib. (C) Abundance of Nfil3 mRNA in CTL. Abundance of 
NFIL3 protein (D) and mRNA levels (E) in naïve CD8+ T cells, TCR activated CD8+ 
T cells and CTL activated for 48 hours and then maintained in IL-2 for 1 day (D1), 
three days (D3) or five days (D5). Analysis of NFIL3 protein abundance in IL-2 
maintained CTL treated with 100 nM Tofacitinib or 20 nM rapamycin (F) or HIF1α 
expressing (Vav-Cre- HIF1αfl/fl) and HIF1α deficient (Vav-Cre+ HIF1αfl/fl) CTL 
maintained in normoxia or switched into hypoxic (1% O2) conditions for eight hours 
(G). Relative abundance of Nfil3 (H) and Slc2a3 (I) mRNA in CTL maintained in 
normoxia or switched into 1% O2 for four hours. Abundance of CD62L mRNA (J) 
and cell-surface protein expression (K) in IL-2 maintained NFIL3+/+ and NFIL3-/- 
CTL. Abundance of perforin mRNA (L) and protein expression (M) in NFIL3+/+ and 
NFIL3-/- CTL. In (C), (H) and (I) the qPCR data were normalized to TBP, in (E) to 
TBP and CD8 and all were expressed relative to (D5) IL-2 maintained CTL in 
normoxia. In (J) and (L), mRNA was normalized to HRPT, and data is shown relative 
to the abundance in NFIL3+/+ CTL. Data in (F) are representative of two biological 
replicates; in (A)-(E) and (H)-(I) data show, or are representative of, three biological 
replicates; in (G) data are representative of eleven (Vav-Cre- HIF1αfl/fl) and ten (Vav-
Cre+ HIF1αfl/fl) biological replicates, four independent experiments; in (J)-(M) data 
are representative of four (NFIL3+/+) and three (NFIL3-/-) biological replicates. Bar 
charts show data from individual biological replicates, color matched where 
appropriate, the bar shows the mean and the errors bars show standard deviation. 
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Supplementary Materials and Methods 
 
Strong anion exchange chromatography (SAX) for peptide fractionation 
Peptide samples for proteomic analysis were fractionated using an Ultimate 3000 
HPLC equipped with an AS24 strong anion exchange (SAX) column as previously 
described (23). For the separation, the buffers used were 10 mM sodium borate, pH 
9.3 (SAX buffer A) and 10 mM sodium borate, pH 9.3, and 500 mM NaCl (SAX 
buffer B). Peptide samples were resuspended in 210 µL 10 mM sodium borate 20% 
(v/v) acetonitrile, pH 9.3 and injected onto the SAX column and separated using an 
exponential elution gradient starting with Buffer A. In total, 16 peptide fractions were 
collected and desalted using Sep-pack C18 96 well desalting plates (Waters). Desalted 
peptides were dried down using a SpeedVac (Genevac). 
 
Liquid Chromatography-Mass Spectrometry 
The chromatography buffers were: HPLC Buffer A (0.1% formic acid), HPLC Buffer 
B (80% acetonitrile, 0.08% formic acid) and HPLC Buffer C (0.1% formic acid). 
Peptides were loaded onto an Acclaim PepMap100 nanoViper C18 trap column (100 
µm inner-diameter, 2cm; Thermo Scientific) in HPLC Buffer C with a constant flow 
of 5 µl/min. After trap enrichment, peptides were eluted onto an EASY-Spray 
PepMap RSLC nanoViper, C18, 2 µm, 100 Å column (75 µm, 50 cm; Thermo 
Scientific) using the following buffer gradient: 2% B (0-3 minutes), 2-40% B (3-128 
minutes), 40-98% B (128-130 minutes), 98% B (130-150 minutes), 98-2% B (150-
151 minutes), and equilibrated in 2% B (151-180 minutes) at a flow rate of 0.3 
µl/minute. The eluting peptide solution was automatically electrosprayed into the 
coupled Linear Trap Quadrupole-Orbitrap mass spectrometer (LTQ-Orbitrap Velos 
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Pro; Thermo Scientific) using an Easy-Spray nanoelectrospray ion source at 50˚C and 
a source voltage of 1.9kV (Thermo Scientific). The mass spectrometer was operated 
in positive ion mode. Full-scan MS survey spectra (m/z 335–1800) in profile mode 
were acquired in the Orbitrap with a resolution of 60,000. Data was collected using 
data-dependent acquisition: the fifteen most intense peptide ions from the preview 
scan in the Orbitrap were fragmented by collision-induced dissociation (normalized 
collision energy, 35%; activation Q, 0.250; and activation time, 10 ms) in the LTQ 
after the accumulation of 5,000 ions. Precursor ion charge state screening was enabled 
and all unassigned charge states as well as singly charged species were rejected. The 
lock mass option was enabled for survey scans to improve mass accuracy. 
 
MaxQuant 1.6.0.1 Run Parameters 
The following search parameters were used: trypsin and LysC were selected as the 
proteases; up to two missed cleavages were permitted; the minimum peptide length 
was set to 6 amino acids; protein N-terminal acetylation, methionine oxidation, 
glutamine to pyroglutamate, glutamine and asparagine deamidation were selected as 
variable modifications; carbamindolyation of cysteine residues was set as a fixed 
modification; MS tolerance of 20 ppm and MS/MS tolerance of 0.5 Da; label free 
quantification was enabled. False discovery rates (FDRs) were set to 0.01 and based 
on hits against the reversed sequence database.This cut-off was applied to individual 
spectra and whole proteins in the MaxQuant output. The match between runs function 
was enabled. Proteins were quantified on the basis of unique (found only in a specific 
protein group) and razor peptides (peptides assigned to a specific protein group 
without being unique to that group) with the re-quantification feature enabled.  
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Primary antibodies for Western blotting 
Membranes were probed with the following primary antibodies: STAT5A/B (CST 
#9363), STAT5A/B pY694/699 (CST, #9359), NFIL3 (CST #14312), granzyme B 
(CST #4275), perforin-1 (CST #3693), HIF1α (R and D systems, clone 241809, cat. 
MAB15361), SMC1 (Bethyl labs, cat. A300-005A), S6 pS235/236 (CST #2211), S6 
(CST #2217), S6K pT389 (CST #9205), S6K (CST #9202), AKT pT308 (CST 
#4056), AKT pS473 (CST #4058), AKT (CST #9272), FOXO1/3A pT24/32 (CST 
#9464), FOXO1 (CST #9454).  
 
Primers for qPCR 
CD8 forward - 5'-GAT ATA AAT CTC CTG TCT GCC CAT C-3'; CD8 reverse - 5'-
ATT CAT ACC ACT TGC TTC CTT GC-3'; CD62L forward - 5'-CCT GTA GCC 
GTC ATG GTC AC-3'; CD62L reverse - 5'-GAA TCA GTA TGG ATC ATC CAT 
C-3'; GLUT1 forward - 5'-CCA GCA GCA AGA AGG TGA-3'; GLUT1 reverse - 5'-
ATG TTT GAT TGT AGA ACT CCT C-3'; HPRT forward - 5'-TGA TCA GTC 
AAC GGG GGA CA-3'; HPRT reverse - 5'-TTC GAG AGG TCC TTT TCA CCA-3'; 
NFIL3 forward - 5'-GCG ATG GTA GCC GGA AGT TGC-3'; NFIL3 reverse - 5'-
CCT GTG CGG GGC TTT CCT GAG-3'; perforin forward - 5'-CGT CTT GGT GGG 
ACT TCA G-3'; perforin reverse - 5'-GCA TTC TGA CCG AGT GGC AG-3'; TBP 
forward - 5'-GGG GAG CTG TGA TGT GAA GT-3'; TBP reverse - 5'-CCA GGA 
AAT AAT TCT GGC TCA T-3'. 
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Supplementary Figures and Figure Legends 
Fig. S1 
 
Fig. S1: Proteomic analysis of CTL 
(A) Experimental workflow for label-free quantitative proteomic analysis of effector 
cytotoxic T cells (CTL). The overlap in protein identification between biological 
replicates is shown in the Venn diagrams for IL-2 maintained CTL (B) and IL-2 
deprived CTL (C). The correlation between estimated copy numbers between the 
biological replicates for IL-2 maintained CTL (D) and IL-2 deprived CTL (E). 
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Fig. S2 
 
Fig. S2: Proteomic analysis of CTL treated with and without Tofacitinib 
The overlap in protein identification between biological replicates is shown in the 
Venn diagrams for IL-2 maintained CTL (A) and IL-2 maintained CTL treated with 
100 nM Tofacitinib for 24 hours (B). The correlation between estimated copy 
numbers between the biological replicates for IL-2 maintained CTL (C) and IL-2 
maintained CTL treated with 100 nM Tofacitinib for 24 hours (D). 
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Fig. S3 
 
Fig. S3: Activation and generation of CTL from NFIL3-/- T cells 
(A) T cells from NFIL3+/+ and NFIL3-/- mice were TCR-activated for 48 hours. Then, 
cells were removed from the activation mix and cultured in IL-2 for a further 5 days. 
The number of cells on each day was counted and graphed. Each point shows the 
mean number of cells from four biological replicates of NFIL3+/+ and three biological 
replicates of NFIL3-/- CTL cultures. Error bars show standard deviation. (B-D) 
Histogram shows the surface expression of CD25 (B), CD69 (C) and CD44 (D) in IL-
2 maintained NFIL3+/+ and NFIL3-/- CTL (after 5 days of IL-2). (E) and (F) western 
blot analysis of AKT phosphorylation (E) and S6K and S6 phosphorylation (F) in 
NFIL3+/+ and NFIL3-/- CTL. For controls NFIL3+/+ CTL were treated with 1 µM 
AKTi (AKT inhibitor) (E) or 20 nM rapamycin (F). In (A-C and E-F), data are 
representative of NFIL3+/+: four biological replicates; NFIL3-/-: three biological 
replicates. In (D), data are representative of two biological replicates per genotype. 
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Supplemental Table Legends 
Table S1. The proteome of IL-2-maintained and IL-2 deprived CTL. 
All the proteins identified in three biological replicates of IL-2 maintained CTL (IL-2) 
and CTL deprived of IL-2 for 24 hours (no IL-2). Copy numbers per cell were 
calculated using histone ruler methodology and used to calculate the ratio of protein 
expression (no IL-2/IL-2). Protein ratios increased by 1.5-fold or greater are colored 
yellow and those decreased by 1.5-fold or greater are highlighted in purple. The 
significance column shows the P values (one sample t-test). Perseus software was 
used to annotate GO terms and KEGG pathways for the proteins. The second tab 
shows the peptide identifications for each protein under each condition. 
 
Table S2. The IL-2 regulated proteome of CTL. 
Proteins identified in three biological replicates of IL-2 maintained CTL (IL-2) and 
CTL deprived of IL-2 for 24 hours (no IL-2) where the copy number ratios are 
statistically (P values £ 0.05, one sample t-test) changed by IL-2 deprivation. In 
addition, proteins found in two or more replicates in the IL-2 maintained CTL and 
absent from the IL-2 deprived CTL are shown. Protein ratios increased by 1.5-fold or 
greater are colored yellow and those decreased by 1.5-fold or greater are highlighted 
in purple. The significance column shows the P values (one sample t-test). Perseus 
software was used to annotate GO terms and KEGG pathways for the proteins.  
 
Table S3. The proteome of IL-2-maintained CTL in the presence or absence of 
Tofacitinib. 
All the proteins identified in three biological replicates of IL-2 maintained CTL (IL-2) 
and IL-2 maintained CTL treated with 100 nM Tofacitinib for 24 hours (IL-2 + Tof). 
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Copy numbers per cell were calculated using histone ruler methodology and used to 
calculate the ratio of protein expression (IL-2 + Tof/IL-2). Protein ratios increased by 
1.5-fold or greater are colored yellow and those decreased by 1.5-fold or greater are 
highlighted in purple. The significance column shows the P values (one sample t-
test). Perseus software was used to annotate GO terms and KEGG pathways for the 
proteins. The second tab shows the peptide identifications for each protein under each 
condition. 
 
 
 
